Germany imported 201,094 kg of medical cannabis in 2025. Average pharmacy prices fell from EUR 8.33 per gram in January to EUR 5.23 in December. The flower list widened from 468 to 724 products over the same year.[1][2]
That combination is hard on loose shipment planning. A rejected batch still ties up capital, planning time, processor capacity, and importer attention. The revenue available to absorb the mistake is smaller than it was at the start of 2025.[2][3]
This is why price compression increases the value of readiness. Importers can tolerate less rework when the market is repricing downward and the shelf is filling up.
Volume did not slow down while prices fell
BfArM's quarterly totals for 2025 came in at 37,686 kg in Q1, 47,707 kg in Q2, 59,076 kg in Q3, and 56,625 kg in Q4.[1] The demand side kept moving even as the market became more crowded.
That matters because falling prices were not a sign of weak demand. They were a sign of stronger supply, more choice, and a harder competitive read for every new origin file.
The retail average lost EUR 3.10 in one year
Bloomwell / Cannamonitor tracked the average German pharmacy price at EUR 8.33 per gram in January 2025 and EUR 5.23 in December.[2] The absolute drop was EUR 3.10 per gram. The percentage drop was about 37%.
That is useful for operators because it tells you what kind of room has left the market. The file still has to work. The spread available to recover from avoidable error is smaller.
The average retail price lost about 37% in one year
Bloomwell / Cannamonitor tracked the market from EUR 8.33 per gram in January to EUR 5.23 in December.[2]
Source: Bloomwell / Cannamonitor Cannabis Barometer, January 2026. • As of 2025[2]
The change shown here is the average German pharmacy price for flower tracked by Bloomwell / Cannamonitor.
"A cheaper market is a stricter market once the batch file reaches the desk."— BfArM import data, Bloomwell / Cannamonitor pricing, GCX wholesale benchmarks
Product count widened while the shelf got cheaper
The same pricing file tracked flower-product growth from 468 listings in January to 724 by December.[2] That is a wider shelf, not just a cheaper one.
More listings change buyer behavior. Importers and pharmacies have more substitutes. A batch that arrives late, arrives in the wrong format, or arrives with open questions now competes inside a denser product field.
The wholesale floor leaves less room for romantic pricing
GCX market reporting shows EU-GMP flower trading inside low single-digit-per-gram bands in 2025.[3] That matters because it sits much closer to the operational cost of failure than old premium route narratives implied.
Once the route is working on that kind of wholesale math, every avoidable deviation takes a larger bite out of the batch.
Country share still concentrated around the largest suppliers
BfArM's 2025 country totals showed Canada at 93,006 kg and Portugal at 55,164 kg.[1] Denmark shipped 9,319 kg, North Macedonia 8,190 kg, Malta 4,858 kg, and Australia 4,190 kg.[1]
The market is broader than it was. It is still led by a short list of countries that can keep product moving through EU-GMP and into Germany at scale.
A rejected batch costs the same time in a cheaper market
The operational disruption of failure does not shrink with the retail price. The importer still has the same release sequence, same pharmacy obligations, and same queue management problem when a batch slips.[1][2]
What shrinks is the money left in the file to absorb it. That is why documentation completeness and method alignment gain value as the market reprices.
Low-cost origin pressure is already visible in the background
GCX reported Colombian cultivation costs as low as about USD 0.06 per gram in spring 2025.[3] Business of Cannabis and Prohibition Partners both tracked South African and other new-origin pressure through 2025.[4][5]
Germany does not buy cultivation cost in the abstract. It buys a released medical file. Low-cost production still changes the negotiation around the route.
Importers now read the batch through price pressure
When margins tighten, the same question becomes sharper. Is this batch likely to move without creating extra work?[2][3]
That turns readiness into a commercial issue. Clean methods, current records, accepted formats, and reliable scheduling reduce friction at the point where friction is getting harder to afford.
The market is broader, though volume still sits with a few origin countries
Canada and Portugal still dominate the German import file, with the rest of the route much smaller by comparison.[1]
Source: BfArM 2025 import totals by country. • As of 2025-12[1]
The long tail is expanding, though the German route is still concentrated at the top.
A cheaper market is a stricter market
Germany's 2025 import surge did not create a forgiving market. It created a larger and less forgiving one.[1][2] The more product the market can choose from, the more expensive avoidable failure becomes for the seller who causes it.
That is the practical lesson of the year. Price compression is a quality story once you get close enough to the batch file.
Primary Sources
- BfArMMedizinalcannabisverkehr – Ein-/Ausfuhr↗
- High Times, citing Bloomwell / CannamonitorGermany's Medical Cannabis Problem Is That It Worked2026-01↗
- Global Cannabis ExchangeSpring 2025 market report2025-04↗
- Business of CannabisProhibition Partners platform launch for European cannabis trends2025-07↗
- Prohibition PartnersGermany: Medical Cannabis Market Overview 20252025-09↗